The endometrium from estrogens alone to TSECs

Climacteric

Volumn 12, Issue 6, 2009, Pages 463-477

  Pickar, J H ^a  

^a PFIZER INC   (United States)

Author keywords

Cancer; Carcinoma; Endometrium; Hyperplasia; Menopause; Progestin; Tissue selective estrogen complex (tsec); Unopposed estrogens

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DROSPIRENONE PLUS ESTRADIOL; ESTERIFIED ESTROGEN DERIVATIVE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTRONE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIMEGESTONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; AMENORRHEA; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CARCINOMA IN SITU; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; ESTROGEN RELEASE; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; HISTORY OF MEDICINE; HORMONAL REGULATION; HOT FLUSH; HUMAN; INCIDENCE; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUAL IRREGULARITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PROTECTION; REVIEW; TREATMENT DURATION; UTERUS BLEEDING; VAGINAL DRYNESS;

ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROGESTINS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 70449657485     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903042790     Document Type: Review

References (102)

1. Brennecke. Zur aetiologie der "endometritis fungosa", speciell der "chronischen hyperplasirenden endometritis olshausen's". Arch Gynakol 1882;20:455-486
2. Cullen TS. Cancer of the Uterus: Its Pathology, Symptomatology, Diagnosis, and Treatment. New York: Appleton-Century-Crofts, Inc., 1900
3. Bäcker J. Gynä kologische sektion des kö nigl. Ungarischen ä rztevereins zu Budapest. Zentrabl Gynäkol 1904;22:735-736
4. Meyer R. Ueber seltener gutartige und zweifelhafte epithelverä nderungen der uterusschleimhaut im vergleich mit der ihnen ähnlichen karzinomformen. Geburtshilfe Gynä kologie 1923;85:440-466
5. Horsley JS. Report of a case of adenocarcinoma of the body of the uterus. Am J Obstet Gynecol 1924;7:106-107
6. Novak E, Martzloff K. Hyperplasia of the endometrium - a clinical and pathological study. Am J Obstet Gynecol 1924;8:385-411
7. Novak E, Yui E. Relation of endometrial hyperplasia to adenocarcinoma of the uterus. Am J Obstet Gynecol 1936;32:674-698
8. Taylor HC. Endometrial hyperplasia and carcinoma of the body of the uterus. Am J Obstet Gynecol 1932;23:309-332
9. Hertig AT, Sommers SC. Genesis of endometrial carcinoma. I. Study of prior biopsies. Cancer 1949;2:946-956
10. Hertig AT, Sommers SC, Bengloff H. Genesis of endometrial carcinoma. III. Carcinoma in situ. Cancer 1949;2:964-971
11. Speert H. The premalignant phase of endometrial carcinoma. Cancer 1952;5:927-944
12. Campbell PE, Barter RA. The significance of a typical endometrial hyperplasia. J Obstet Gynaecol Br Commonw 1961;68:668-672
13. Hall KV. Irregular hyperplasias of the endometrium. Acta Obstet Gynecol Scand 1957;36: 306-323
14. Gusberg SB, Kaplan AL. Precursors of corpus cancer. IV. Adenomatous hyperplasia as stage of carcinoma of the endometrium. Am J Obstet Gynecol 1963;87:662-678
15. Copenhaver EH. Atypical endometrial hyperplasia. Obstet Gynecol 1959;13:264-268
16. Sherman AI, Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol 1979;135:947-956
17. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A longterm study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-412
18. Gusberg SB. Precursors of corpus carcinoma. Estrogens and adenomatous hyperplasia. Am J Obstet Gynecol 1947;54:905-927
19. Beutler HK, Dockerty MB, Randall LM. Precancerous lesions of the endometrium. Am J Obstet Gynecol 1963;86:433-443
20. Taylor HC. The pathology of the ovarian hormone. With special reference to its role in tumor development. Am J Obstet Gynecol 1938;36:332-349
21. Dockerty MB, MacCarty W. Granulosa cell tumors. Am J Obstet Gynecol 1939;37: 425-434
22. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191
23. Jackson RL, Dockerty MB. The Stein-Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 1957;73:161-173
24. Sommers SC, Hertig AT, Bengloff H. Genesis of endometrial carcinoma. II. Cases 19 to 35 years old. Cancer 1949;2:957-963
25. Herrell WE. Studies on the endometrium in association with the normal menstrual cycle, with ovarian dysfunctions, and cancer of the uterus. Am J Obstet Gynecol 1939;37:559-572
26. Speert H. Carcinoma of the endometrium in young women. Surg Gynecol Obstet 1949;88: 332-336
27. Schroeder H. Ueber das vorkommen von follikelanlagen in neubildungen. Ein beitrag zur entstehung der eierstocksgeschwü ltse. Arch Gynakol 1901;64:193-236
28. Smith G, Johnson L, Hertig A. Relation of ovarian stromal hyperplasia and thecoma of the ovary to endometrial hyperplasia and carcinoma. N Engl J Med 1942;226:364.
29. Woll E, Hertig AT. The ovary in endometrial carcinoma with notes on the morphological history of the aging ovary. Am J Obstet Gynecol 1948;56:617-633
30. Ingram JM, Jr, Novak E. Endometrial carcinoma associated with feminizing ovarian tumors. Am J Obstet Gynecol 1951;61:774-789
31. Diddle AW. Granulosa- and theca-cell ovarian tumors: prognosis. Cancer 1952;5:215-228
32. Larson JA. Estrogens and endometrial carcinoma. Obstet Gynecol 1954;3:551-572
33. Dockerty MB, Mussey E. Malignant lesions of the uterus associated with estrogen-producing ovarian tumors. Am J Obstet Gynecol 1951;61:147-153
34. de Waard F. On the aetiology of endometrial carcinoma. Acta Endocrinol 1958;29:279-294
35. Shaw W, Dastur B. The association of certain ovarian cells with endometrial cancer. Br Med J 1949;2:113-117
36. Novak ER, Mohler DI. Ovarian stromal changes in endometrial cancer. Am J Obstet Gynecol 1953;65:1099-1110
37. Judd HL, Lucas WE, Yen SS. Serum 17bestradiol and estrone levels in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 1976;43:272-278
38. Judd HL, Davidson BJ, Frumar AM, et al. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1980;136:859-871
39. Nyholm HC, Nielsen AL, Lyndrup J, et al. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 1993;100:1115-1119
40. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485-497
41. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-1135
42. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001;84:975-981
43. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425-432
44. Fremont-Smith M, Meigs JV, Graham RM, Gilbert HH. Cancer of endometrium and prolonged estrogen therapy. JAMA 1946;131: 805-808
45. Speert H. Corpus cancer: clinical, pathological and etiological aspects. Cancer 1948;1:584-603
46. Gusberg SB, Moore DB, Martin F. Precursors of corpus cancer. II. A clinical and pathological study of adenomatous hyperplasia. Am J Obstet Gynecol 1954;68:1472-1481
47. Bromberg YM, Liban E, Laufer A. Early endometrial carcinoma following prolonged estrogen administration in an ovariectomized woman. Obstet Gynecol 1959;14:221-226
48. Kistner RW, Krantz KE, Lebherz TB, et al. Endometrial cancer: rising incidence, detection and treatment. J Reprod Med 1973;10: 53-74
49. Quint BC. Changing patterns in endometrial adenocarcinoma: a study of 291 consecutive cases at a large private hospital, 1960-1973. Am J Obstet Gynecol 1975;122:498-501
50. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-1170
51. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-1167
52. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294: 1262-1267
53. Gray LA, Sr, Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol 1977;49:385-389
54. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313:969-972
55. Weiss NS, Szekely DR, English DR, Schweid AI. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979;242: 261-264
56. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993;81: 265-271
57. Pike MC, Peters RK, Cozen W, et al. Estrogen- progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116
58. Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986;124:434-441
59. Lacey JV, Jr, Brinton LA, Lubin JH, et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1724-1731
60. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375
61. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76: 25-31
62. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234-1240
63. Prestwood KM, Kenny AM, Unson C, Kulldorff M. The effect of low dose micronized 17b-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 2000;85: 4462-4469
64. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999;181:71-79
65. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997;157:2609-2615
66. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996;276:1397-1403
67. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer 1959;12:1106-1122
68. Varga A, Henriksen E. Clinical and histopathologic evaluation of the effect of 17- alpha-hydroxyprogesterone-17-n-caproate on endometrial carcinoma. Obstet Gynecol 1961; 18:658-672
69. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216-222
70. Wentz WB. Treatment of persistent endometrial hyperplasia with progestins. Am J Obstet Gynecol 1966;96:999-1004
71. Eichner E, Abellera M. Endometrial hyperplasia treated by progestins. Obstet Gynecol 1971;38:739-742
72. Wentz WB. Progestin therapy in endometrial hyperplasia. Gynecol Oncol 1974;2:362-367
73. Gambrell RD, Jr. The prevention of endometrial cancer in postmenopausal women with progestogens. Maturitas 1978;1:107-112
74. Gambrell RD, Jr. Estrogens, progestogens and endometrial cancer. J Reprod Med 1977;18: 301-306
75. Whitehead MI, Campbell S. Endometrial histology, uterine bleeding, and oestrogen levels in menopausal women receiving oestrogen therapy and oestrogen/progestogen therapy. Endometrial Carcinoma. London: Bailliere Tindall, 1978:65-80.
76. Whitehead MI. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas 1978;1:87-98
77. Whitehead MI, King RJ, McQueen J, Campbell S. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/ progestogen therapy. J R Soc Med 1979;72:322-327
78. Rosenwaks Z, Wentz AC, Jones GS, et al. Endometrial pathology and estrogens. Obstet Gynecol 1979;53:403-410
79. Bewtra C, Kable WT, Gallagher JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med 1988;33:205-208
80. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67: 327-332
81. Weinstein L. Efficacy of a continuous estrogen- progestin regimen in the menopausal patient. Obstet Gynecol 1987;69:929-932
82. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990;162:1534-1539
83. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994;170:1213-1223
84. Samsioe G, Dvorak V, Genazzani AR, et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas 2007;57:171-181
85. de Cecco L., Gerbaldo D, Fulcheri E, et al. Endometrial response in sequential cyclic therapy assessed with associated hysteroscopy and histology. Maturitas 1992;15:199-208
86. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-1748
87. Bouchard P, De Cicco-Nardone F, Spielmann D, Garcea N. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17b-estradiol/ trimegestone versus 1 or 2 mg 17b-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol 2005; 21:142-148
88. Samsioe G, Boschitsch E, Concin H, et al. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. Climacteric 2006;9:368-379
89. Byrjalsen I, Thormann L, Meinecke B, Riis BJ, Christiansen C. Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol 1992;79:523-528
90. Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17b-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004;7:103-111
91. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008
92. Kharode Y, Bodine PVN, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149: 6084-6091
93. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404 (Pubitemid 40734275)
94. Komm BS, Pickar JH. Tissue selective estrogen complex (TSEC): a new paradigm for menopausal therapy. Presented at the 6th International Menopause Society Workshop. Menopause and Ageing, Quality of Life and Sexuality, Pisa, Italy, December 2006. Complete Proceedings Collection, http://www. 6thimsworkshop.com/ sito/inside-pages/proceedings/pickar.pdf
95. Stovall DW, Utian W, Gass M, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-517
96. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium - a pilot study. Menopause 2004;11:167-175
97. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med 2007;52:93-96
98. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial protection in menopausal therapy with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens. Fertil Steril 2009; doi: 10.1016/ j.fertnstert.2009.05.094
99. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009; doi: 10.1016/j.fertnstert. 2009.02.093
100. Lobo RA, Pinkerton JV, Gass MLS, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertil Steril 2009; doi: 10.1016/j.fertnstert.2009.03. 113
101. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/ CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009; doi: 10.1016/ j.fertnstert.2009.05.093
102. Koninckx PR, Spielmann D. A comparative 2-year study of the effects of sequential regimens of 1 mg 17b-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Gynecol Endocrinol 2005;21: 82-89 (Pubitemid 41345500)